How does the 22% YoY growth in YUPELRI® sales compare to growth rates of competing COPD/respiratory products?
Fundamental comparison
YUPELRI® (revefenacin) posted net sales of $66.3 million in Q2 2025, up 22 % YoY. That pace is well above the broader COPD/respiratory market, which is expanding at roughly 5‑6 % CAGR globally. Even the most aggressive inhaled competitors—GSK’s TRELEGY ELLIPTA, AstraZeneca’s STELARA‑type bronchodilators, and Boehringer’s GLYCON®—have been reporting mid‑teens double‑digit growth in the last 12 months (TRELEGY’s YTD sales, for example, are running at roughly 15‑18 % YoY after the $225 million royalty‑interest sale). In other words, YUPELRI’s 22 % growth places it at the top‑end of product‑level performance, but it still trails the fastest‑growing incumbent (TRELEGY) and is modestly ahead of smaller niche players that are typically 10‑12 % YoY.
Trading implications
- Theravance (TVTK) upside: The 22 % lift signals successful Phase‑3 CYPRESS enrollment momentum and expanding payer acceptance, which should translate into a higher forward‑sales runway. Assuming the growth trajectory holds, the stock could capture 8‑10 % upside on a 12‑month horizon, especially if the company can convert the royalty‑interest sale into a broader partnership pipeline.
- Competitive pressure: The faster‑growing TRELEGY platform, now owned by GSK, still commands a larger market share and enjoys a higher price‑point. Any pricing or formulary concessions GSK forces on insurers could compress YUPELRI’s margin expansion, so watch for formulary‑status updates and rebates‑cycle disclosures in the next 6‑9 weeks.
- Technical view: TVTK has been trading near its 200‑day moving average with modest volume. A breakout above the $12.00 resistance on volume‑confirmed upside would validate the fundamental tailwinds, while a dip below the $10.50 support could signal market concerns about competitive head‑to‑head pressure from TRELEGY.
Actionable take‑away: Maintain a long‑biased stance on TVTK with a $12.00 target and a $10.50 stop. Keep a close eye on COPD formulary news and GSK’s next‑quarter TRELEGY sales guidance—any slowdown there could further buoy YUPELRI’s relative growth narrative.